Business Description
PHAXIAM Therapeutics SA
ISIN : FR001400K4B1
Compare
Compare
Traded in other countries / regions
PHXM.FrancePHXM.USA2E40.Germany0QSS.UK IPO Date
2013-05-07Description
Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.44 | |||||
| Equity-to-Asset | 0.56 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | -1.02 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EPS without NRI Growth Rate | 44.4 | |||||
| 3-Year FCF Growth Rate | 33.8 | |||||
| 3-Year Book Growth Rate | -45.9 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.22 | |||||
| 9-Day RSI | 53.97 | |||||
| 14-Day RSI | 47.47 | |||||
| 6-1 Month Momentum % | -32 | |||||
| 12-1 Month Momentum % | -64.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.78 | |||||
| Quick Ratio | 1.78 | |||||
| Cash Ratio | 1.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20 | |||||
| Shareholder Yield % | 35.09 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | 0.89 | |||||
| ROA % | 0.41 | |||||
| ROIC % | 1.08 | |||||
| ROC (Joel Greenblatt) % | -95.52 | |||||
| ROCE % | -8.25 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 3.02 | |||||
| PE Ratio without NRI | 3.08 | |||||
| PB Ratio | 0.49 | |||||
| Price-to-Tangible-Book | 2.98 | |||||
| EV-to-EBIT | 1.17 | |||||
| EV-to-EBITDA | 1.17 | |||||
| EV-to-FCF | 0.13 | |||||
| Price-to-Graham-Number | 0.3 | |||||
| Price-to-Net-Current-Asset-Value | 8.94 | |||||
| Earnings Yield (Greenblatt) % | 85.76 | |||||
| FCF Yield % | -177.72 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PHAXIAM Therapeutics SA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | 0.977 | ||
| Beta | 2.42 | ||
| Volatility % | 45.29 | ||
| 14-Day RSI | 47.47 | ||
| 14-Day ATR (€) | 0.07557 | ||
| 20-Day SMA (€) | 2.945 | ||
| 12-1 Month Momentum % | -64.89 | ||
| 52-Week Range (€) | 2.6 - 11.7 | ||
| Shares Outstanding (Mil) | 6.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PHAXIAM Therapeutics SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PHAXIAM Therapeutics SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
PHAXIAM Therapeutics SA Frequently Asked Questions
What is PHAXIAM Therapeutics SA(XPAR:PHXM)'s stock price today?
The current price of XPAR:PHXM is €2.95. The 52 week high of XPAR:PHXM is €11.70 and 52 week low is €2.60.
When is next earnings date of PHAXIAM Therapeutics SA(XPAR:PHXM)?
The next earnings date of PHAXIAM Therapeutics SA(XPAR:PHXM) is 2024-05-12 Est..
Does PHAXIAM Therapeutics SA(XPAR:PHXM) pay dividends? If so, how much?
PHAXIAM Therapeutics SA(XPAR:PHXM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers